Is AMPH a Good Stock to Buy? The Bull and Bear Case (2026)
Last updated November 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Amphastar Pharmaceuticals (AMPH) rests on BAQSIMI volume versus net price: BAQSIMI is the single largest product, at a record ~$58.8 million in Q3 2026 (up ~10% year over year) after ~$45.5 million in Q2 and ~$185 million in 2025. The bear case rests on legacy erosion is the most visible risk: glucagon kit sales fell ~37% in Q3 2026 on competition, and epinephrine fell ~19% as releases from the IMS plant slowed. Analysts covering it publish targets from $20.00 to $30.00 against a $28.25 share price on November 20, 2026, so even the professionals disagree by 41% of their own average. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
AMPH key stats
At $28.25 on November 20, 2026, Amphastar Pharmaceuticals (AMPH) has a market cap of $1.2B and a P/E of 13.0 on trailing earnings (8.4 on forward earnings).
- Market cap
- $1.2B
- P/E (trailing)
- 13.0
- P/E (forward)
- 8.4
- EPS (trailing 12 months)
- $2.18
- Price to book
- 1.5
- Beta
- 0.94
Market cap, P/E and yield are measured at the $28.25 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Amphastar Pharmaceuticals (AMPH)?
The last two weeks for Amphastar Pharmaceuticals, as of November 22, 2026: the price move, the next earnings date, and what analysts changed.
- AMPH closed at $28.25 on November 20, 2026, down 3.8% over the past five trading days (from $29.37).
Prices are daily closes from Yahoo Finance. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
Amphastar Pharmaceuticals (Nasdaq: AMPH), based in Rancho Cucamonga, California, develops, manufactures and sells technically difficult generic and proprietary injectable, inhalation and intranasal medicines. It makes more than 30 products, and its own active pharmaceutical ingredients (including insulin API) through a subsidiary in China. The largest sellers are BAQSIMI, the nasal glucagon rescue spray bought from Eli Lilly in 2023, the over-the-counter asthma inhaler Primatene MIST, and hospital staples such as epinephrine, lidocaine and glucagon kits. Most volume flows through group purchasing organizations, wholesalers and retailers. The latest reported quarter, Q3 2026 (reported November 5, 2026), was a record: net revenue of ~$207.6 million rose ~8% year over year and ~13% from Q2, GAAP net income was ~$37.8 million, and adjusted EPS of $1.14 (up from $0.93) beat the ~$0.86 consensus, a second straight beat after Q2's $0.91 against ~$0.61. BAQSIMI hit a record ~$58.8 million, up ~10% on volume, and Primatene MIST a record ~$31.5 million, up ~9%, while the new ipratropium inhaler (~$6.6 million, still the only generic on the market) and teriparatide (~$6.4 million) added growth. Glucagon kits fell ~37% and epinephrine ~19%, the latter because of slower releases from the IMS plant under FDA remediation. Gross margin slipped to ~48% from ~51% on lower net pricing and remediation costs of about $2-3 million in the quarter. Over the trailing twelve months revenue is ~$746 million and GAAP net income ~$99 million. Management expects Q4 2026 sales to grow in the high single digits from Q4 2025, declined to give 2027 guidance, and the board added $50 million to the buyback authorization. The investment picture is a contest between a cheap multiple and a shrinking legacy base. At $28.15 on November 20, 2026 the market value is ~$1.2 billion, after heavy buybacks (~$74 million in the first half of 2026 alone). That is ~13x trailing GAAP EPS of ~$2.18 and ~8.4x forward EPS of ~$3.35. Against that, the South El Monte plant has been under an FDA warning letter since July 2026, BAQSIMI net pricing still faces 340B and rebate pressure even as volumes grow, and the biosimilar insulin aspart and a GLP-1 generic are not expected to sell until 2027. The shares have climbed from below $20 before the Q2 report to $28.15 (up ~6% year to date and ~11% over one year, 52-week range $16.65 to $31.00), above the ~$24.50 average of six analyst targets.
The bull case: what would have to be true for $30.00
The most optimistic published target on AMPH is $30.00, +6.2% from the $28.25 share price on November 20, 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. BAQSIMI volume versus net price
BAQSIMI is the single largest product, at a record ~$58.8 million in Q3 2026 (up ~10% year over year) after ~$45.5 million in Q2 and ~$185 million in 2025. Unit volume drove the gain, though duplicate 340B discounts still cost ~$2.2 million of net price in the quarter. Management has cited peak sales potential of ~$250 to ~$275 million and has been exiting several unprofitable international markets since July to focus on the US. Hitting the first $175 million contract-year milestone triggered a $100 million payment to Lilly due in Q3 2026, so continued volume growth matters both for revenue and for justifying that acquisition cost.
2. New generic and inhalation launches
Launches are carrying the growth. Generic ipratropium bromide HFA, approved in February 2026 with 180 days of first-filer exclusivity, sold ~$8.4 million in its first quarter and ~$6.6 million in Q3, and Amphastar is still the only generic on the market. Teriparatide (launched December 2025) sold ~$6.4 million in Q3, iron sucrose (August 2025) keeps adding volume, and Primatene MIST set a record at ~$31.5 million on a price increase and higher volume. These products carry higher margins than the legacy book. The open question is durability: ipratropium exclusivity is time-limited, and generic pricing typically compresses as more entrants arrive. Q3 gross margin of ~48%, down from ~51%, shows pricing and plant costs already working against the mix.
3. Insulin biosimilars and the 2027 pipeline
The largest long-term lever is insulin. Amphastar makes its own insulin API and has a biosimilar insulin aspart (AMP-004) on file with the FDA, plus a GLP-1 generic ANDA (AMP-018), with commercialization for both expected in 2027 and no firm launch date. The company says its filed and in-development generics and biosimilars target US markets worth more than ~$6 billion combined by IQVIA data. Management has described the GLP-1 generic as a limited opportunity because of competition and noted three or four competing insulin aspart products, so the insulin approval is the bigger swing factor. Two other filings, AMP-005 and AMP-017, slipped from the first half to the second half of 2027, and AMP-104, a lower-global-warming Primatene MIST formulation, is targeted for filing by the end of 2028.
4. Cash flow and buybacks
Amphastar generated ~$175 million of operating cash flow over the trailing twelve months, including ~$43 million in Q3 2026, but free cash flow was only ~$9 million after capital spending and the BAQSIMI milestone. It has used cash aggressively on its own stock: shares outstanding fell to ~42.5 million at July 31, 2026 from ~47 million a year earlier, the first half of 2026 saw ~$74 million of repurchases, and in November the board authorized another $50 million. Total debt is ~$692 million (mostly 2029 convertible notes and a term loan) against ~$231 million of cash at September 30. A shrinking share count supports per-share earnings even when net income is flat, which is part of why adjusted EPS beat estimates.
The bear case: what would have to be true for $20.00
The most pessimistic published target is $20.00, -29.2% from the current price. It is neither a floor nor a forecast; it is roughly what one analyst thinks Amphastar Pharmaceuticals is worth if the risks below bite instead of the drivers above.
Legacy erosion is the most visible risk: glucagon kit sales fell ~37% in Q3 2026 on competition, and epinephrine fell ~19% as releases from the IMS plant slowed. BAQSIMI net pricing is under pressure from rebates, 340B discounts and payer mix, so prescription growth does not translate one-for-one into revenue. Regulatory risk rose in July 2026 when the FDA issued a warning letter to the IMS plant in South El Monte, California, citing cGMP problems in investigations, environmental monitoring and equipment; production continues, but remediation cost about $2-3 million in Q3, management expects somewhat higher costs for the next two or three quarters, backorders stood at ~$12.5 million, and the FDA can take further action. Pipeline timing is uncertain, since insulin aspart already passed an earlier Q1 2026 goal date without approval and two other filings slipped into the second half of 2027. The balance sheet carries ~$692 million of debt against ~$231 million of cash. Two founders and executives have pledged shares as loan collateral, and a forced sale by a lender could pressure the stock; insiders also sold about $1.1 million of shares in November 2026 filings. Tariffs, drug pricing reform and Chinese API exposure add policy risk, and the stock trades above the average analyst target after a ~28% three-month rally.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding AMPH already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on AMPH
6 analysts cover AMPH, with an average target of $24.50 (-13.3% against $28.25) and a split of 0 buy, 6 hold, 1 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the AMPH forecast and price target page.
How is AMPH valued?
Market cap, P/E and dividend yield at today's price are in the AMPH key stats above. The business figures below come from Amphastar Pharmaceuticals's reported results as of November 2026 and change when it next reports.
- Revenue (TTM): ~$746 million
- Revenue growth (Q3 2026, YoY): ~8%
- GAAP net income (TTM): ~$99 million
- Q3 2026 adjusted EPS: $1.14 (vs ~$0.86 expected)
- Gross margin (Q3 2026): ~48%
- Total debt / cash: ~$692 million / ~$231 million
As of November 2026: Priced at the $28.15 close on November 20, 2026, Amphastar trades near 13x trailing GAAP earnings, 8.4x forward estimates and about 8.4x EV/EBITDA. The gap between GAAP and adjusted earnings comes mainly from amortization of the BAQSIMI intangible and share-based compensation. Net debt is roughly ~$460 million, and the six analysts in the consensus rate the stock Hold on average with a mean target of ~$24.50, below the current price.
How do you decide if AMPH is a buy?
Whether AMPH is a buy is easier to judge through four narrower questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold AMPH indirectly through an index or sector ETF before adding more.
What would change your mind on AMPH
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: BAQSIMI volume versus net price stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
- Bear case breaks if: legacy erosion is the most visible risk: glucagon kit sales fell ~37% in Q3 2026 on competition, and epinephrine fell ~19% as releases from the IMS plant slowed fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the AMPH stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about AMPH against your real portfolio and see your actual exposure before deciding.
Your questions about Amphastar Pharmaceuticals
Ask Walnut's AI anything about AMPH and see how it fits what you own.
FAQ
Is AMPH a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on BAQSIMI volume versus net price, with revenue (ttm) at ~$746 million. The bear case rests on legacy erosion is the most visible risk: glucagon kit sales fell ~37% in Q3 2026 on competition, and epinephrine fell ~19% as releases from the IMS plant slowed. Analysts covering it are spread from $20.00 to $30.00, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.
Should I sell AMPH?
+
Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Legacy erosion is the most visible risk: glucagon kit sales fell ~37% in Q3 2026 on competition, and epinephrine fell ~19% as releases from the IMS plant slowed. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $20.00, -29.2% from the $28.25 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.
What is the bull case for AMPH?
+
BAQSIMI volume versus net price. BAQSIMI is the single largest product, at a record ~$58.8 million in Q3 2026 (up ~10% year over year) after ~$45.5 million in Q2 and ~$185 million in 2025. The most optimistic analyst target on AMPH is $30.00, +6.2% from the $28.25 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for AMPH?
+
Legacy erosion is the most visible risk: glucagon kit sales fell ~37% in Q3 2026 on competition, and epinephrine fell ~19% as releases from the IMS plant slowed. BAQSIMI net pricing is under pressure from rebates, 340B discounts and payer mix, so prescription growth does not translate one-for-one into revenue. Regulatory risk rose in July 2026 when the FDA issued a warning letter to the IMS plant in South El Monte, California, citing cGMP problems in investigations, environmental monitoring and equipment; production continues, but remediation cost about $2-3 million in Q3, management expects somewhat higher costs for the next two or three quarters, backorders stood at ~$12.5 million, and the FDA can take further action. Pipeline timing is uncertain, since insulin aspart already passed an earlier Q1 2026 goal date without approval and two other filings slipped into the second half of 2027. The balance sheet carries ~$692 million of debt against ~$231 million of cash. Two founders and executives have pledged shares as loan collateral, and a forced sale by a lender could pressure the stock; insiders also sold about $1.1 million of shares in November 2026 filings. Tariffs, drug pricing reform and Chinese API exposure add policy risk, and the stock trades above the average analyst target after a ~28% three-month rally. The most pessimistic published target is $20.00, -29.2% from the current price, which is roughly what one analyst thinks the stock is worth if these risks bite and the drivers do not.
What does Amphastar Pharmaceuticals do?
+
Maker of hard-to-make injectable and inhalation drugs, including BAQSIMI nasal glucagon.
What would have to change for AMPH to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (BAQSIMI volume versus net price) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (legacy erosion is the most visible risk: glucagon kit sales fell ~37% in Q3 2026 on competition, and epinephrine fell ~19% as releases from the IMS plant slowed) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does Amphastar Pharmaceuticals do?
+
Amphastar develops, manufactures and sells technically challenging generic and proprietary medicines in injectable, inhalation and intranasal forms. It sells more than 30 products, including BAQSIMI nasal glucagon for severe low blood sugar, the over-the-counter Primatene MIST asthma inhaler, hospital injectables such as epinephrine and lidocaine, and newer generics including ipratropium bromide, iron sucrose and teriparatide. It also makes active pharmaceutical ingredients, including insulin, through its ANP subsidiary in China. Most sales go through group purchasing organizations, drug wholesalers and retailers in the US. Revenue over the trailing twelve months is ~$746 million. The company is headquartered in Rancho Cucamonga, California, and is led by co-founder and CEO Dr. Jack Zhang. Founders and insiders own a meaningful stake, which keeps strategy closely tied to management's long-term view.
How did Amphastar's latest quarter go?
+
In Q3 2026, reported November 5, 2026, net revenue was a record ~$207.6 million, up ~8% year over year and ~13% from Q2. GAAP net income was ~$37.8 million, and adjusted EPS was $1.14 against estimates near $0.86 and $0.93 a year earlier. BAQSIMI (~$58.8 million, up ~10%) and Primatene MIST (~$31.5 million, up ~9%) both set records, and ipratropium (~$6.6 million) and teriparatide (~$6.4 million) added growth. Glucagon kits fell ~37% and epinephrine ~19%. Gross margin fell to ~48% from ~51% on lower net pricing and IMS remediation costs. Management guided Q4 sales to high single digit growth, added $50 million to the buyback, and the stock rose sharply after the report.
How has AMPH stock performed in 2026?
+
AMPH closed at $28.15 on November 20, 2026, up about 6.4% year to date and 11% over one year. Most of that came late: the shares rose about 28% over three months and 12% in the past month after the Q2 and Q3 earnings beats. The 52-week range is $16.65 to $31.00.
Walnut is informational, not investment advice, and gives no verdict on AMPH. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 20, 2026. Verify current figures with your broker before acting on them.